Richard Staines discusses what has become one of the worst deals in pharma’s history – AbbVie’s purchase of Stemcentrx and its lung cancer drug Rova-T. Rova-T was supposed to be the cancer ...

AbbVie reported better-than-expected fourth-quarter earnings. Strong demand for the company's Skyrizi and Rinvoq autoimmune therapeutics has helped offset the decline in Humira sales since losing ...

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its ...

AbbVie CEO Robert Michael will soon add the role of board chairman to his résumé. Michael, who became CEO of the North Chicago-based pharmaceutical giant last summer, will assume duties as ...

AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, the biopharmaceuticals giant delivered 6% sales growth and $2.12 in ...

AbbVie (ABBV) announced that its board of directors has unanimously elected CEO Robert Michael to assume the additional position of chairman, effective July 1. He will succeed Richard Gonzalez ...

AbbVie has moved to shore up its pipeline following ... tesirine), which was at the heart of its $5.8 billion takeover of Stemcentrx in 2016. It also has a follow-up ADC targeting c-Met in phase ...

NORTH CHICAGO, Ill., Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the ...